Project Title: Eligibility of miRNAs modified by docetaxel in prostate cancer cells
to plasma biomarkers in patients responsive or no more responsive to docetaxel
Funding: ITT Istituto Toscano Tumori
Partners: CNR-IFC (Pisa), CNR-IIT (Pisa), AUSL n. 8 Arezzo
Project Coordinator: Dr. Milena Rizzo (IFC-CNR)
- Duration: 3 years (2016-2018).
Project value: 345,000 Euro
AIM OF THE PROJECT:
Several piece of evidence indicate
that cancer cells are or become resistant to anticancer drugs depending on whether resistant cells were
already existing or arising during treatment. Since experience shows that tumors often become resistant to anticancer drugs,
new molecules and novel strategies are necessary to reduce the negative impact of resistance in tumor therapy.
In this project we will study miRNA biomarkers for predicting resistance to docetaxel and cabazitaxel in Prostate cancer.
Last update: October 20th, 2015
[Marco's home page]